Sihuan Pharm

Development History

2012-TODAYNew Journey
  • In 2012, Sihuan completed its headquarters building in Zhangjiawan, Beijing.
  • The group then launched a dual-engine strategy in innovative biopharma and medical aesthetics.
  • In 2012, Sihuan acquired Xuanzhu Biopharmaceutical to strengthen innovative R&D.
  • In 2014, Huisheng Biopharma was established to enter diabetes and complication areas.
  • In 2014, Sihuan signed exclusive agency deals for Korean botulinum toxin and hyaluronic acid.
  • In 2021, Xuanzhu acquired Kangming BIO to enhance large-molecule innovation capacity.
  • From 2020 to 2022, Xuanzhu and Huisheng each completed two financing rounds.
  • From 2021 to 2023, core aesthetics products entered commercialization and the business accelerated.
2010-2012Leapfrog Development
  • In 2010, Sihuan introduced Morgan Stanley and relisted in Hong Kong.
  • With capital strength, Sihuan expanded the cardiovascular portfolio through M&A and strategic cooperation.
  • The group upgraded manufacturing and formed three production bases for chemicals, TCM and APIs.
  • Management systems were advanced to improve governance and sustain growth.
  • These moves supported a decade of rapid expansion above industry average growth.
2007-2009Rapid Growth
  • In 2007, Sihuan listed in Singapore and expanded through acquisitions.
  • The company established its "cooperation and sharing" philosophy and cardiovascular focus strategy.
  • Sihuan built a distinctive academic-promotion and distributor-driven marketing model.
  • A nationwide sales network formed strong market reach and competitive advantage.
2001-2006Start-up Stage
  • Sihuan originated from Hainan Yangpu Xinte Pharmaceutical founded in 2001.
  • In 2003, it acquired Beijing Sihuan and moved from outsourced to owned manufacturing.
  • In 2005, it established a cardiovascular research institute with its own R&D team.
  • Within five years, Sihuan built integrated capabilities in R&D, production and sales.